Generating AI analysis...
Revenue
$11.87B
++4.66% YoY
EPS (Basic)
$-5.89
-645.37% YoY
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $11.87B | $11.34B | +4.66% |
Cost of Revenue | $2.93B | $2.57B | +14.26% |
Net Income | $-11.91B | $2.26B | -626.57% |
EPS (Basic) | $-5.89 | $1.08 | -645.37% |
EPS (Diluted) | $-5.89 | $1.07 | -650.47% |
R&D Expense | $2.69B | $2.32B | +16.11% |
SG&A Expense | $2.37B | $1.76B | +34.34% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $99.03B | $94.28B | +5.04% |
Current Assets | $28.67B | $27.09B | +5.84% |
Total Liabilities | $82.48B | $62.4B | +32.19% |
Current Liabilities | $25.82B | $19.09B | +35.30% |
Stockholders' Equity | $16.49B | $31.82B | -48.18% |
Cash & Equivalents | $9.33B | $8.99B | +3.72% |
Long-Term Debt | $52.36B | $37.33B | +40.26% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $2.83B | $2.97B | -4.58% |
Investing Cash Flow | $-19.62B | $-210M | -9241.90% |
Financing Cash Flow | $14.64B | $-3.05B | +580.13% |
Dividends Paid | $1.21B | $1.2B | +1.34% |
Share Buybacks | $0 | $250M | -100.00% |
D&A | $2.53B | $2.43B | +4.24% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | -100.4% | — | — |
ROE | -72.2% | — | — |
ROA | -12.0% | — | — |
Current Ratio | $1.11 | — | — |
Debt to Equity | $5.002 | — | — |
Other companies in Pharmaceuticals